

Supplementary table 1: The clinical characteristics of participants at the time of switch to E/F/C/T.

Characteristics	NNRTI-based (n = 453)	INSTI-based (n = 70)	PIs-based (n = 82)	P-value
Age (years) median (IQR)	34 (27, 45)	34 (28, 47)	35 (29, 53)	0.040
Sex (male) (%)	437 (96.4)	67 (95.7)	77 (93.9)	0.540
HBV coinfection (%)	5 (1.1)	0 (0)	3 (3.7)	0.310
HCV coinfection (%)	5 (1.1)	1 (1.4)	3 (3.7)	0.230
Syphilis coinfection (%)	158 (34.9)	15 (21.4)	23 (28.0)	0.090
Infection routes (%)				0.010
Heterosexual	87 (19.2)	19 (27.1)	16 (19.5)	
Homosexual	315 (69.5)	35 (50)	52 (63.4)	
Others	51 (11.3)	16 (22.9)	14 (17.1)	
TDF (%)	384 (84.8)	67 (95.7)	82 (100)	< 0.001
Laboratory data				
median (IQR)				
CD4 (cells/ μ L)	622 (454, 808)	520 (350, 709)	726 (381, 929)	0.030
CD8 (cells/ μ L)	904 (660, 1206)	1150 (724, 1576)	1062 (630, 1487)	0.070
Leukocyte ($\times 10^9$ /L)	5.98 (5.12, 7.22)	5.93 (4.73, 6.7)	6.9 (5.37, 7.77)	0.210
Hemoglobin (g/L)	155 (147, 164)	153 (144, 166)	154 (144, 162)	0.490
Platelets ($\times 10^9$ /L)	236 (204, 275)	202 (190, 242)	248 (194, 286)	0.010
Cholesterol (mmol/L)	4.60 (4.07, 5.18)	4.27 (3.82, 4.91)	4.64 (4.06, 5.2)	0.220

Triglycerides (mmol/L)	1.41 (0.95, 2.31)	1.14 (0.78, 1.89)	2.44 (1.38, 3.29)	<0.001
Creatinine (µmol/L)	70.8 (64.2, 79.6)	77.2 (66.1, 85.1)	71.8 (62.3, 86)	<0.001
Glucose (mmol/L)	5.9 (5.49, 6.40)	5.76 (5.43, 6.15)	5.82 (5.9, 6.58)	0.400
ALT (IU/mL)	25.9 (18, 36)	18 (14, 36)	16 (12, 26.75)	<0.001
AST (IU/mL)	20 (17, 26)	18 (16, 22)	17 (14, 20)	0.030
Duration of previous treatment (years)	3.84 (2.15, 5.45)	1.93 (1.34, 2.54)	3.34 (1.82, 4.14)	<0.001

INTIs: Integrase inhibitors; NNRTI: Non-nucleotide reverse transcriptase inhibitor; PI: Protease inhibitor; ALT: Alanine aminotransferase; IQR: Interquartile range. ALT: alanine transaminase; AST: aspartate transaminase; TDF: Tenofovir.